Agios Provides Update On Phase 2 Trial Of Tebapivat In Sickle Cell Disease
AGIO•Phase 2 tebapivat update
July 21 (Reuters) - Agios Pharmaceuticals Inc AGIO.O:
- Agios provides update on phase 2 trial of tebapivat in sickle cell disease
- Agios Pharmaceuticals - will not advance tebapivat in sickle cell disease
- Agios Pharmaceuticals - primary endpoint achieved by up to 47.1% in tebapivat arms; 33.3% in placebo arm
- Agios Pharmaceuticals - tebapivat safety consistent with prior sickle cell disease trials
- Agios Pharmaceuticals - FDA priority review for mitapivat in sickle cell disease; PDUFA date November 1, 2026
